Evercore ISI analyst Liisa Bayko maintained a Buy rating on 89bio (ETNB – Research Report) yesterday and set a price target of $33.00. The ...

New York State Common Retirement Fund increased its stake in shares of 89bio, Inc. (NASDAQ:ETNB – Free Report) by 24.3% in ...

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical ...

Bio Inc (ETNB) has disclosed a new risk, in the Demand category. 89Bio Inc. faces a significant risk if the market ...

Read Our Latest Stock Report on ETNB 89bio Stock Performance ETNB stock opened at $8.88 on Monday. 89bio has a 12 month low of $5.99 and a 12 month high of $16.63. The firm has a 50 day moving ...

Roche RHHBY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking label expansion for its ...

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...

“2024 marks a tremendous year of execution and progress for 89bio, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of ...

"2024 marks a tremendous year of execution and progress for 89bio, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of enrollment in ...